<DOC>
	<DOCNO>NCT00744419</DOCNO>
	<brief_summary>The purpose study determine body use eliminate pantoprazole , drug use treat GERD . This pharmacokinetic ( PK ) study . PK measure much drug blood long take leave body . It hypothesize young infant need low dose old child achieve PK measurement . The result study used determine best dose drug use age group . Pantoprazole drug use decrease acid production . The use pantoprazole approve use child . Pantoprazole approve use acid-related stomach disorder adult .</brief_summary>
	<brief_title>Intravenous ( IV ) Pantoprazole Gastroesophageal Reflux Disease ( GERD ) Neonates Infants</brief_title>
	<detailed_description>Gastroesophageal reflux , regurgitation gastric content esophagus , gastroesophageal reflux disease , display symptom complication regurgitation , common infant . Daily reflux present 50 % infant young 3 month 66 % 4 month age . GERD primarily attribute low esophageal sphincter relaxation . Between 5-9 % infant less one year age GERD require acid suppression . Complications associate GERD include failure thrive , apnea , wheeze , recurrent aspiration , poor feeding , refusal feed , irritability , severe case , acute life-threatening event . Pantoprazole proton pump inhibitor suppress final step gastric acid production bind H+-K+-ATPase enzyme system surface parietal cell gastric epithelium . This cause reduction acid production regardless stimulus present . Pantoprazole use therapy GERD , erosive esophagitis , gastritis , gastric ulceration , duodenal ulceration prophylaxis stress gastritis hospitalize patient . Pantoprazole metabolize mainly hepatic cytochrome P-450 CYP2C19 hypothesize metabolize high rate child compare adult . However , metabolism proton pump inhibitor slower infant &lt; 10 week age . Clinical study ongoing use oral pantoprazole infant child . Acid suppression frequently require hospitalized infant treat GERD . In child critically ill , oral administration acid suppressive agent relatively contraindicate therefore intravenous alternative intravenous pantoprazole imperative . Intravenous pantoprazole well tolerate pharmacokinetic study child age 1 16 year . No systematic study do determine pharmacokinetics intravenous pantoprazole infant less 1 year age therefore study meet identified unmet need address knowledge deficit population . The aim study determine pharmacokinetics pantoprazole sodium injection evaluate safety tolerability single multiple intravenous dos preterm neonates infant 0-11 month age use population pharmacokinetics . In addition , genotyping CYP2C19 CYP3A4 polymorphism perform .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>1 . Signed informed consent HIPAA document parent/legal guardian . 2 . Hospitalized premature neonate ( Post menstrual age ( PMA ) 28 &lt; 34 week ) , neonate ( PMA 34 44 week ) , infant ( PMA &gt; 44 week 11 month ) . 3 . Clinical indication acid suppression presumptive diagnosis GERD base clinical symptom and/or objective test diagnostic GERD . 4 . Body weight least 750 gram ( base blood volume require study participation ) . 1 . Previous adverse reaction proton pump inhibitor 2 . History gastrointestinal anomaly , eosinophilic esophagitis , unrepaired tracheal esophageal fistula liver disease 3 . Unstable cardiovascular , renal , hepatic , hematologic endocrine disease 4 . History acute lifethreatening event due GERD 5 . History hepatitis B hepatitis C 6 . Use PPI 's within 24 hour study drug administer 7 . Known human immunodeficiency virus ( HIV ) acquire immune deficiency syndrome 8 . Clinically significant laboratory value : Aspartate aminotransferase ( AST ) alanine aminotransferase ( AST ) &gt; 2 time upper limit normal ( ULN ) age Total bilirubin &gt; 2 time ULN age Alkaline phosphatase &gt; 2 time ULN age 10.Use histamine2 receptor blocker ( eg . Cimetidine , famotidine , ranitidine , nizatidine ) sucralfate , misoprostol , prokinetic agent ( eg . urecholine , erythromycin , metoclopramide ) antacid bismuth preparation within 24 hour test article administration . 11.Any disorder require chronic use warfarin , oxcarbazepine , topiramate , carbamezapine , rifampin phenytoin . 12.Currently participate another investigational drug trial participate study within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>28 Weeks</minimum_age>
	<maximum_age>11 Months</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>GERD</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pantoprazole</keyword>
	<keyword>neonate</keyword>
	<keyword>infant</keyword>
</DOC>